Donepezil Tablet
Product Images NDC 82009-120

16 FDA label images from Quallent Pharmaceuticals Health Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil (NDC 82009-120). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Donepezilchemicalstructure (Donepezilchemicalstructure)

Donepezilchemicalstructure (Donepezilchemicalstructure)
Chemical structure of Donepezil hydrochloride, showing the molecular arrangement including methoxy groups, a piperidine ring, and a benzyl group attached to the core structure, with the hydrochloride indicated.*
FDA Label Image

Donepezilfigure2 (Donepezilfigure2)

Donepezilfigure2 (Donepezilfigure2)
A cumulative percentage curve chart depicting changes from baseline in cognitive function measured by ADAS-cog scores among patients treated with Donepezil Hydrochloride 5 mg/day, 10 mg/day, or placebo. The chart compares the cumulative percentage of patients achieving different point improvements or no change.*
FDA Label Image

Donepezilfigure3 (Donepezilfigure3)

Donepezilfigure3 (Donepezilfigure3)
A bar chart showing the percentage of patients rated on the CIBIC-Plus scale across seven categories: Markedly Improved, Markedly Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse. The chart compares three groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and Placebo.*
FDA Label Image

Donepezilfigure4 (Donepezilfigure4)

Donepezilfigure4 (Donepezilfigure4)
A line graph showing the mean ADAS-cog change from baseline over weeks of drug treatment for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The vertical axis represents cognitive change scores with clinical improvement at the top and clinical decline at the bottom. The horizontal axis represents treatment duration in weeks up to 15. Lines indicate that higher doses correspond to greater clinical improvement compared to placebo, with error bars showing standard error of the mean (SEM).*
FDA Label Image

Donepezilfigure5 (Donepezilfigure5)

Donepezilfigure5 (Donepezilfigure5)
A cumulative percentage of patients line graph showing change from baseline on the x-axis and cumulative percentage of patients on the y-axis, comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The chart includes markers for 7 points, 4 points, and no change, with a table summarizing percentage of patients achieving specific changes in ADAS cognitive scores for each treatment group.*
FDA Label Image

Donepezilfigure6 (Donepezilfigure6)

Donepezilfigure6 (Donepezilfigure6)
A bar chart comparing the percentage of patients by CIBIC-plus Rating categories for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The x-axis shows categories from Markedly Improved to Markedly Worse, while the y-axis represents the percentage of patients. Separate bars for each group indicate patient distribution across rating categories.*
FDA Label Image

Donepezilfigure7 (Donepezilfigure7)

Donepezilfigure7 (Donepezilfigure7)
A line graph showing the clinical effect of Donepezil hydrochloride 10 mg/day versus placebo over 6 months of drug treatment. The vertical axis measures the mean change from baseline in SIB (Severe Impairment Battery) scores, with clinical improvement indicated above baseline and clinical decline below. Donepezil shows an increase in SIB scores indicating improvement, while placebo shows a decline over time.*
FDA Label Image

Donepezilfigure8 (Donepezilfigure8)

Donepezilfigure8 (Donepezilfigure8)
A cumulative percentage plot showing the change from baseline in Severe Impairment Battery (SIB) scores for patients treated with Donepezil hydrochloride 10 mg/day compared to placebo. The x-axis represents the SIB change from baseline, and the y-axis shows the cumulative percentage of patients.*
FDA Label Image

Donepezilfigure9 (Donepezilfigure9)

Donepezilfigure9 (Donepezilfigure9)
A line graph depicting ADCS-ADL change from baseline (mean ± SE) over six months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The vertical axis shows change from baseline, with clinical improvement above and decline below. The horizontal axis represents months of drug treatment at 0, 3, and 6 months. Donepezil group shows less clinical decline compared to placebo over time.*
FDA Label Image

Donepezilfigure10 (Donepezilfigure10)

Donepezilfigure10 (Donepezilfigure10)
A line chart comparing the cumulative percentage of patients versus ADCS-ADL change from baseline for Donepezil Hydrochloride 10 mg/day and placebo groups. The x-axis represents ADCS-ADL change from baseline, and the y-axis shows cumulative percentage of patients, with two distinct curves marked by symbols for each group.*
FDA Label Image

Donepezilfigure11 (Donepezilfigure11)

Donepezilfigure11 (Donepezilfigure11)
A line graph illustrating SIB change from baseline (LS mean ±SE) over 24 weeks of drug treatment for Donepezil Hydrochloride at 23 mg/day and 10 mg/day. The x-axis shows weeks of drug treatment from 0 to 24, and the y-axis shows SIB change from baseline ranging from -3 to 5, indicating clinical decline to clinical improvement.*
FDA Label Image

Donepezilfigure12 (Donepezilfigure12)

Donepezilfigure12 (Donepezilfigure12)
A cumulative percentage curve graph showing the change from baseline in SIB (Severe Impairment Battery) scores for patients treated with Donepezil Hydrochloride at dosages of 10 mg/day and 23 mg/day. The x-axis represents SIB change from baseline, ranging from positive to negative values, while the y-axis shows the cumulative percentage of patients, from 0 to 100 percent. The graph compares the effect of the two dosage levels over a range of SIB score changes.*
FDA Label Image

Donepezilfigure13 (Donepezilfigure13)

Donepezilfigure13 (Donepezilfigure13)
A bar chart displaying the percentage of patients categorized by CIBIC-plus rating groups comparing Donepezil Hydrochloride 23 mg/day and 10 mg/day dosages. The categories include Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse, with bars showing relative patient distribution for each dosage.*
FDA Label Image
FDA Label Image

Donepeziltablets5mg500slabel (Donepeziltablets5mg500slabel)

Donepeziltablets5mg500slabel (Donepeziltablets5mg500slabel)
Label for Donepezil Hydrochloride Tablets, USP 5 mg by Quallent Pharmaceuticals Health LLC. The label indicates 500 tablets in the package with storage instructions and contact information, including guidance to refer to the package insert for full prescribing information.*
FDA Label Image

Donepeziltablets10mg500slabel (Donepeziltablets10mg500slabel)

Donepeziltablets10mg500slabel (Donepeziltablets10mg500slabel)
Label for Donepezil Hydrochloride Tablets, USP 10 mg, manufactured by Quallent Pharmaceuticals Health LLC. The label indicates a quantity of 500 tablets, prescription only, with storage information and contact details. It includes a barcode and states the manufacturer as Hetero Labs Limited, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.